Budesonide Inhalation In Treatment Of Acute Exacerbations Of Chronic Obstructive Pulmonary Disease Effects On Serum Cytokine IL-17,IL-8,and TNF-a

Objective:This paper was foucs on budesonide inhalation in treatment of acute exacerbations of chronic obstructive pulmonary disease on serum cytokine IL-17, IL-8 and TNF-aMethods:According to the Chinese Medical Association diagnostic criteria for COPD in 2007, Acute exacerbation of COPD diagnostic criteria:①acute exacerbation of the disease refers to the process, short-term cough, sputum, shortness of breath, and (or) breathing increased sputum volume, increased mucus was thick or dense nature, may be associated with fever and other symptoms,②COPD III level, that is, FEV1/FVC<70%,30%≤FEV1<50%; COPD IV level, that is, FEV1/FVC<70%, FEV1<30% or FEV1<50% of predicted, those with respiratory failure; Selected 120 patients with acute exacerbation were randomly divided into budesonide group, methylprednisolone group, budesonide group of 61 patients, methylprednisolone group of patients 59. And in gender, age, duration of disease, when selected blood gas analysis, pulmonary function test, etc. There was no significant difference (P> 0.05), determination of budesonide inhalation treatment of chronic obstructive pulmonary disease patients with acute exacerbation of serum IL17, IL8, TNFa changes and with intravenous injection of methylprednisolone treatment for comparison. Data with the mean±standard deviation SPSS 16.0 statistical analysis package, before and after treatment with paired t test, t test comparing the two groups.Results:budesonide group, methylprednisolone group treated after 10 days the PaCO2 level decreased in the budesonide group before and after treatment PaCO2 levels were significantly decreased (P<0.05, t=4.571), methylprednisolone group after treatment, PaCO2 levels were significantly decreased (P<0.05, t=5.025), in the budesonide group and the methylprednisolone group before treatment PaCO2 difference was not statistically significant (P> 0·05, before and after treatment t=-1.986,-1.604) After Inhaled budesonide treatment of chronic obstructive pulmonary disease with acute exacerbation The patient's serum IL-17,IL-8, TNFa changed significantly,Budesonide group and the methylprednisolone group before treatment IL-17, IL-8, TNF-a levels, were not statistically significant, Budesonide group and the methylprednisolone group after treatment, IL-17, IL-8, TNF-a levels were no significant difference1. IL-17 In the budesonide group and the methylprednisolone group before treatment serum IL-17 levels were higher than after treatment. Budesonide group in the pre-treatment serum levels of IL-17 was higher than after treatment ((t=3.941, P<0.01), before treatment with methylprednisolone group and budesonide serum levels of IL-17 were no significant difference (t=0.210, P>0.05). methylprednisolone group after treatment, IL-17 level decreased significantly more than in the budesonide group, but no statistical difference between the two groups t-test (t=0.162, P> 0.05).2:TNF-a budesonide group and the methylprednisolone group before treatment serum TNF-a levels were higher than after treatment (P<0.01) in the budesonide group pre-treatment serum levels of TNF-a is higher than after treatment (t=2.907, P<0.05), methylprednisolone pre-treatment serum levels of TNF-a is higher than after treatment ((t=2.125, P<0.05), decreased TNFa methylprednisolone group was significantly higher than in the budesonide group, but no statistics significant difference (t=0.758, p> 0.05).3:IL-8 In the budesonide group and the methylprednisolone group before treatment serum IL-8 levels were higher than after treatment (P<0.01). Budesonide group pre-treatment serum IL-8 levels higher than after treatment (t=2.467, P<0.05),in methylprednisolone group serum IL-8 levels before treatment was higher than after treatment (t=2.996, P 0.01), before and after treatment in the budesonide group and the methylprednisolone group serum IL-8 levels were no significant differences (t =0.969 and 1.425, p> 0.05)Conclusion:Budesonide inhalation treatment of chronic obstructive pulmonary disease with acute exacerbation can inhibited the inflammatory cells.and reduced inflammation-related cytokines IL-17, IL-8, TNF-a released, decreased neutrophil accumulation and release of hazardous substances so as to reduce airway inflammation. Budesonide and methyl- prednisolone treatment of chronic obstructive pulmonary disease with acute exacerbation were equivalent.